Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition
These therapies offer personalized, effective options for MG management, though challenges in cost and access remain. Future research should address long-term outcomes and biomarkers.
Authors
- Neeharika Thottempudi (ORCID: https://orcid.org/0009-0003-2956-4766)
- Burton J. Tabaac (ORCID: https://orcid.org/0000-0001-7862-5471)
- Verena Samara
- Olivia Franke
Institutions
- University of Nevada, Reno (US)
- Carson Tahoe Regional Medical Center (US)
Publication Details
- Journal
- American Journal of Therapeutics
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1097/mjt.0000000000002052
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00